Analysis of KRAS and NRAS mutations in Greek patients with metastatic Colorectal Cancer (mCRC) on the registry of the Gastro-intestinal Cancer Stud...

Date 29 June 2016
Event ESMO World Congress on Gastrointestinal Cancer 2016
Session ESMO World Congress on Gastrointestinal Cancer 2016 - Abstracts book
Presenter J. Souglakos
Citation Annals of Oncology (2016) 27 (2): 1-85. 10.1093/annonc/mdw199
Authors J. Souglakos1, Z. Saridaki1, N. Gouges2, A. Voutsina3, M. Tzardi4, A. Kalikaki3, M. Sfakianaki3, A. Athanasiadis5, E. Xynos2, I. Boukovinas5, K. Natori6, S. Ishihara6, D. Nagase6, Y. Mitsui7, A. Sakai8, M. Kato7, K. Arai9, Y. Kuraishi6, H. Izumi6, P. Khatri10, P. Kumari11
  • 1Laboratory of Tumor Cell Biology, School of Medicine, University of Crete and Department of Medical Oncology, University General Hospital, Heraklion, Greece, /
  • 2Gastro-Intestinal Cancer Study Group, Iraklio, Greece, /
  • 3Laboratory of Tumor Cell Biology, School of Medicine, University of Crete, Heraklion, Greece, /
  • 4Laboratory of Pathology, University General Hospital, Heraklion, Greece, /
  • 5Hellenic Oncology Research Group, Athens, Greece, /
  • 6Toho University Medical Center Oomori Hospital, Oota-ku, Japan, /
  • 7Division of Hematology & Oncology, Department of Medicine, Toho University Medical Center Oomori Hospital, Oota-ku, Japan, /
  • 8Division of Hematology & Oncology Department of Medicine Toho University Medical Center Oomori Hospital, Oota-ku, Japan, /
  • 9Toho University Faculty of Nursing, Oota-ku, Japan, /
  • 10Acharya Tulsi Cancer Hospital & Research Center & Allied Hospitals, Bikaner, India, /
  • 11Acharya Tulsi Regional Cancer Treatment and Research Center, Bikaner, India, /

Abstract

Several studies show that mutational profiles could influence treatment decisions in patients with metastatic CRC (mCRC). KRAS mutational status was the first step in biomarkers development in the era of molecular targeted therapies. Recently, NRAS mutational status was identified as an independent prognostic factor for the response to treatment with anti-EGFR moAbs. The analysis of NRAS mutations is now mandatory for the administration of anti-EGFR moAbs for the treatment of patients with mCRC. The aim of this observational study was to assess the feasibility of the KRAS/NRAS mutational analysis in patients with metastatic colorectal cancer in Greece and to identify any correlations of RAS mutational status with known clinical characteristics and histopathologic features.